Physician profile
Leslie J Tarlow
NPI 1528282852
$58,147.07
in general payments reported to CMS, 2019-2025
13 companies · $19K in 2025
The $19K reported for 2025 was more than what 99% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14K · 2022: $16K · 2023: $7,088 · 2024: $3,219 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Travel and Lodging: $4,540 · Food and Beverage: $4,012 · Consulting Fee: $3,250 · Honoraria: $3,120 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,812.50 |
| Travel and Lodging | $4,540.13 |
| Food and Beverage | $4,011.73 |
| Consulting Fee | $3,250.00 |
| Honoraria | $3,120.00 |
| Education | $174.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $21,921.15 | 2021-2025 | Vumerity, Tysabri |
| Genzyme Corporation | $9,001.25 | 2023-2025 | |
| Tg Therapeutics, INC. | $8,988.50 | 2024-2025 | |
| Genentech USA, INC. | $6,304.76 | 2021-2024 | Ocrevus |
| Horizon Therapeutics Plc | $5,032.74 | 2023 | Uplizna |
| Emd Serono, INC. | $2,202.77 | 2022-2025 | Mavenclad, Mavenclad |
| Genentech, INC. | $1,262.50 | 2021-2024 | Ocrevus |
| Novartis Pharmaceuticals Corporation | $1,131.80 | 2021-2025 | Kesimpta |
| Cycle Pharmaceuticals INC | $915.00 | 2023 | |
| Janssen Pharmaceuticals, INC | $780.00 | 2021 | |
| Celgene Corporation | $511.88 | 2021-2023 | Zeposia |
| Alexion Pharmaceuticals, INC. | $61.94 | 2023-2024 | Soliris, Ultomiris |
| Amgen INC. | $32.78 | 2024 | Uplizna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Tarlow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.